MDxHealth SA (MDXH)

Market Cap	76.61M
Revenue (ttm)	84.71M
Net Income (ttm)	-41.95M
Shares Out	47.29M
EPS (ttm)	-1.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	396,074
Open	1.550
Previous Close	1.570
Day's Range	1.550 - 1.645
52-Week Range	0.350 - 4.640
Beta	-393,789.79
Analysts	Strong Buy
Price Target	7.00 (+332.1%)
Earnings Date	Nov 6, 2024

About MDXH

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient’s previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personaliz...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Nov 4, 2021
• Employees: 300
• Stock Exchange: NASDAQ
• Ticker Symbol: MDXH
• Website: https://mdxhealth.com

Financial Performance

In 2023, MDxHealth's revenue was $70.19 million, an increase of 89.43% compared to the previous year's $37.05 million. Losses were -$43.10 million, -2.14% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for MDXH stock is "Strong Buy." The 12-month stock price forecast is $7.0, which is an increase of 332.10% from the latest price.

Price Target

$7.0

(332.10% upside)

Analyst Consensus: Strong Buy